Plato Investment Management Ltd decreased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 92.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,024 shares of the biotechnology company’s stock after selling 24,793 shares during the period. Plato Investment Management Ltd’s holdings in BioMarin Pharmaceutical were worth $121,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Activest Wealth Management bought a new position in shares of BioMarin Pharmaceutical in the fourth quarter worth approximately $26,000. Quent Capital LLC bought a new position in shares of BioMarin Pharmaceutical in the third quarter worth approximately $28,000. Smartleaf Asset Management LLC grew its holdings in shares of BioMarin Pharmaceutical by 92.5% in the third quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 360 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of BioMarin Pharmaceutical in the third quarter worth approximately $40,000. Finally, Parallel Advisors LLC grew its holdings in shares of BioMarin Pharmaceutical by 62.2% in the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 295 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.
BioMarin Pharmaceutical Stock Performance
Shares of BioMarin Pharmaceutical stock opened at $52.58 on Tuesday. The stock has a market cap of $10.16 billion, a price-to-earnings ratio of 38.38, a PEG ratio of 0.40 and a beta of 0.23. The firm’s 50-day moving average is $56.06 and its 200 day moving average is $56.33. BioMarin Pharmaceutical Inc. has a 1 year low of $50.76 and a 1 year high of $66.28. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on BioMarin Pharmaceutical
Insider Transactions at BioMarin Pharmaceutical
In related news, EVP Gregory R. Friberg sold 6,326 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $60.38, for a total value of $381,963.88. Following the transaction, the executive vice president owned 37,578 shares in the company, valued at $2,268,959.64. The trade was a 14.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Charles Greg Guyer sold 16,486 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total value of $996,743.56. Following the completion of the transaction, the executive vice president directly owned 79,953 shares of the company’s stock, valued at approximately $4,833,958.38. This trade represents a 17.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 26,093 shares of company stock worth $1,555,389. 0.85% of the stock is currently owned by company insiders.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.
The company’s commercial portfolio includes several approved therapies targeting inherited disorders.
Featured Stories
- Five stocks we like better than BioMarin Pharmaceutical
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
